Inhibitor development in correlation to factor VIII genotypes

Haemophilia

Volumn 8, Issue SUPPL. 2, 2002, Pages 23-29

  Oldenburg, J ^a,b,c   El Maarri, O ^b   Schwaab, R ^b  

^a Institute of Transfusion Medicine and Immune Hematology   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Epitopes; Factor VIII; Gene mutation; Haemophilia A; HLA system; Inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; EPITOPE; HLA DQ ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; GENE DELETION; GENETIC HETEROGENEITY; GENOTYPE; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MISSENSE MUTATION; MOLECULAR GENETICS; NONSENSE MUTATION; PRIORITY JOURNAL; RISK FACTOR; SUBSTITUTION THERAPY; TREATMENT FAILURE;

ANTIBODIES; ANTIBODY FORMATION; EPITOPES; FACTOR VIII; GENOTYPE; HEMOPHILIA A; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MUTATION; RISK FACTORS;

EID: 0036249147     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1351-8216.2001.00134.x     Document Type: Article

References (37)

1. Factor VIII inhibitors in patients with haemophilia A. epidemiology of inhibitor development and induction of immune tolerance for factor VIII
2. Incidence of inhibitors in haemophiliacs. A review of the literature
3. Haemophilia A. mutation type determines risk of inhibitor formation
4. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors to factor VIII
5. HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party
6. Advances toward Gene Therapy for Haemophilia at the Millennium
7. The Factor VIII Structure and Mutation Resource Site: Hamsters, Version 4
8. Risk factors for inhibitor development in haemophilia A
9. Partial correction of a severe molecular defect in haemophilia A, because of errors during expression of the factor VIII gene
10. Small deletion/ insertion mutations within poly-A-runs of the factor VIII gene mitigate the severe haemophilia A phenotype
11. Factor VIII Ise (R2159 C) in a patient with mild haemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes
12. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation
13. A novel cause of mild/moderate haemophilia A. mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor
14. Haemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure
15. Structure of the C2 domain of human factor VIII at 1.5 A resolution
16. Incidence of inhibitors in haemophilia A patients - A review of recent studies of recombinant and plasma-derived factor VIII concentrates
17. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with haemophilia A. Update of safety, efficacy and inhibitor development after seven study years. ISTH Florence
18. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs). A 7.3 year update. WFH The Hague
19. Increased frequency of inhibitors in African American haemophilia A patients. ASH Nashville
20. The role of Genetics in Inhibitor Formation
21. Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies
22. HLA antigens and factor VIII antibody in classic haemophilia. European study group of factor VIII antibody
23. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in haemophilia A
24. Factor VIII antibodies in haemophilia A
25. Specifity and promiscuity among naturally processed peptides bound to HLA-DR alleles
26. A murine monoclonal anti-factor VIII inhibitory antibody and two human factor VIII inhibitors bind to different areas within a twenty amino acid segment of the acidic region of factor VIII heavy chain
27. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII
28. Characterization of a factor VIII immunogenic site using factor VIII synthetic peptide 1687-1695 and rabbit anti-peptide antibodies
29. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules
30. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain
31. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII
32. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site
33. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor
34. The life cycle of coagulation factor VIII in view of its structure and function
35. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization
36. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild haemophilia A
37. The missense mutation Arg593 → Cys is related to antibody formation in a patient with mild haemophilia A